News | Nuclear Imaging | June 23, 2016

Molecular Imaging of Neuroendocrine Tumors Optimizes Radiotherapy Dose

Study shows the use of PET and SPECT tailors radionuclide treatment for neuroendocrine cancer patients and reduces the risk of toxicity

neuroendocrine tumors, NET, radiotherapy dose, PET, SPECT, SNMMI 2016

Comparison of Ga-68-DOTATOC PET/CT with Y-90 DOTATOC PET/CT. Although the positron associated with Y-90 is rarely emitted, there is still sufficient signal to acquire a quantitative PET/CT image of Y-90 DOTATOC after a therapeutic administration. The white arrows indicate kidneys and the yellow arrows tumor. Credit: University of Iowa

June 23, 2016 — Aggressive neuroendocrine cancer is something of a dark horse — a rare, elusive and persevering force linked to discouraging long-term survival rates. Researchers at the 2016 Annual Meeting of the Society of Nuclear Medicine and Molecular Imaging (SNMMI) — held June 11-15 in San Diego — presented a molecular imaging technique that allows oncologists to set patients’ radiotherapy doses right at that critical limit of delivering the most powerful kill to neuroendocrine tumors (NETs) while protecting vulnerable vital organs.

The delicate balance of administering the maximum safe dose is called personalized dosimetry, and it can vary widely between patients. This poses a problem for clinicians. A number of radiotherapies that marry a small but potent amount of radioactive material and a targeted molecular compound have been gaining traction as progressive treatments for malignant NETs, which can develop wherever nerve cells and hormone-producing endocrine cells are present (e.g., gastrointestinal tract, pancreas, lungs, thyroid). Scientists are taking pre-emptive action by using already-available molecular imaging systems to determine the optimal dose of one such peptide-receptor radionuclide therapy known as yttrium-90 DOTA0-Tyr3-octreotide (Y-90 DOTATOC).

“DOTATOC is a peptide that binds with somatostatin receptors that are often highly expressed in neuroendocrine cancers,” said Mark T. Madsen, Ph.D., University of Iowa in Iowa City, Iowa. “With molecular imaging, we are able to see whether the DOTATOC imaging agent is taken up by the tumor. If it is, we know that the Y-90 DOTATOC radiotherapy will also reach the tumor and be able to kill tumor cells.”

The objective here is to set the bar for the highest possible therapeutic radiation dose to NETs that does not exceed toxic radiation levels to the kidneys, which take on the brunt of the residual drug that does not bind to its targets. Results of this research showed that the use of positron emission tomography (PET) and single photon emission computed tomography (SPECT), which image physiological functions of the body such as peptide receptor activity, led to dramatically altered dosimetry in all participating patients.

For this study, researchers worked with 12 patients with malignant NETs to find an adaptive approach to personalized dosimetry during three cycles of radiotherapy. All adult patients underwent 4.44 GBq of Y-90 DOTATOC and pediatric patients received 1.85 GBq per m2 during the first course of treatment. Patients were also given an infusion of amino acids as a protective measure against kidney toxicity.

The researchers evaluated blood and renal dosimetry after the first and second courses of radiotherapy to discern the best possible dose of Y-90 DOTATOC for successive courses. Dosimetry was performed by imaging patients with quantitative PET/CT about five hours after administration of Y-90 DOTATOC, followed by quantitative SPECT/CT imaging at 24, 48 and 72-hour intervals after injection. Y-90 burden and kidney mass were determined from reconstructed PET and CT images and verified using phantoms — inanimate objects that act just like patients’ vital organs during imaging and therapy.

The researchers were able to complete 20 dosimetry evaluations for the 12 subjects involved in the study. Y-90 activity accumulation in the kidneys ranged from 1.4 to 3.6 percent. The kidney dose ranged from 0.6 to 2.7 mGy per MBq, and the blood dose ranged from 0.04 to 0.24 mGy per MBq. This led to marked changes in subsequent cycles of treatment. The dose of radiotherapy was not increased for two injections in children, and one patient’s treatment ended after only one course of treatment. For the rest of the subjects, the dose of radiotherapy was increased in eight courses and decreased in three courses. Over all, the prescribed dose of radiotherapy was altered by more than 15 percent in a total of 11 courses of radiotherapy.

“Our approach combines the advantages of quantitative Y-90 PET and SPECT imaging to gather all the information required to accurately estimate kidney dose,” said Madsen. “We expect better outcomes in radionuclide therapy treatment with fewer complications because we will be able to adjust patient dose either up or down as needed.”

While this method of personalized dosimetry was used to determine the maximum dose that is safe for kidneys, this imaging technique could be equally used to determine the most effective dose to combat NETs. Further studies should elucidate how best to apply this technique to improve the standard of neuroendocrine cancer care.

For more information: www.snmmi.org

Related Content

Philips Launches IntelliSpace Discovery Research Platform at RSNA
Technology | Artificial Intelligence | November 20, 2018
Ahead of the 2018 Radiological Society of North America Annual Meeting (RSNA), Nov. 25-30 in Chicago, Royal Philips...
Bay Labs and Northwestern Medicine Enroll First Patient in AI Echocardiography Study
News | Cardiovascular Ultrasound | November 19, 2018
Medical artificial intelligence (AI) company Bay Labs and Northwestern Medicine announced that the first patient has...
Immune Inflammatory Levels Linked to Disease-Free Survival in Prostate Cancer
News | Prostate Cancer | November 19, 2018
Data from a validation study of a high-risk prostate cancer trial suggests that higher levels of pretreatment...
GE Healthcare Recalls Millennium Nuclear Medicine Systems
News | Nuclear Imaging | November 15, 2018
GE Healthcare announced it is recalling its Millennium Nuclear Medicine Systems due to an incident in which the the top...
Life Image and Mendel.ai Bringing Artificial Intelligence to Clinical Trial Development
News | Artificial Intelligence | November 15, 2018
Life Image and Mendel.ai announced a new strategic partnership that will facilitate the adoption and enhancement of...
Artificial Intelligence Predicts Alzheimer's Years Before Diagnosis
News | Neuro Imaging | November 14, 2018
Artificial intelligence (AI) technology improves the ability of brain imaging to predict Alzheimer’s disease, according...
Merit Medical Completes Acquisition of Cianna Medical
News | Women's Health | November 14, 2018
Disposable device manufacturer Merit Medical Systems Inc. announced the closing of a definitive merger agreement to...
Researchers Awarded 2018 Canon Medical Systems USA/RSNA Research Grants
News | Radiology Imaging | November 13, 2018
The Radiological Society of North America (RSNA) Research & Education (R&E) Foundation recently announced the...
Subtle Medical Showcases Artificial Intelligence for PET, MRI Scans at RSNA 2018
News | Artificial Intelligence | November 13, 2018
At the 2018 Radiological Society of North America annual meeting (RSNA 2018), Nov. 25-30 in Chicago, Subtle Medical...
University of Missouri Research Reactor First U.S. I-131 Supplier in 30 Years

MURR is the only supplier of I 131 in the United States and the first U.S. supplier since the 1980s. Image courtesy of University of Missouri

News | Radiopharmaceuticals and Tracers | November 13, 2018
The University of Missouri Research Reactor (MURR) recently shipped its first batch of Iodine-131 (I-131), a...